Abstract: Disclosed herein are computer-implemented methods and systems for predicting transplant rejection. The methods and system may calculate a predicted probability of whether or an extent to which transplant rejection in a transplant recipient will occur may be calculated based on a score. The score may be calculated based on transplant recipient data and one or more parameter weights. The transplant recipient data may comprise transplant donor-derived cell-free DNA (dd-cfDNA) and one or more other types of parameters, such as one or more clinical parameters, one or more functional parameters, one or more immunological parameters, one or more transplant recipient characteristics, or one or more transplant characteristics. In some embodiments, the parameters used for calculating the predicted probability does not comprise a histological parameter.

Abstract: The present disclosure relates to methods of monitoring the status of an allograft in a transplant recipient, as well as to methods of monitoring and adjusting immunosuppressive therapies being administered to the transplant recipient.

Abstract: Disclosed herein is a system and associated methods for determining one or more scores representative of a pre- or post-transplant recipient's activities and behaviors for self-care. The system may determine one or more scores from a plurality of activities and behaviors. The pre- or post-transplant recipient's input(s) and/or measurement information may be related to one or more metrics, and the score(s) may be determined relative to one or more associated metric targets. The score(s) may represent the pre- or post-transplant recipient's self-care status. The importance of a given metric to a pre- or post-transplant recipient's progress for self-care may vary depending on one or more factors such as the pre- or post-transplant recipient's health, age, gender, medical history, or the like, and one or more metric weights may be used to change the impact a metric has on the pre- or post-transplant recipient's score(s).

Abstract: The present disclosure relates to methods of monitoring allogeneic cells, for example, in samples from a recipient of allogeneic cells from one or two genetically related or genetically unrelated sources, via measurement of cell DNA, as well as to methods of assessing treatment efficacy and/or monitoring and adjusting therapies.